Results 291 to 300 of about 857,003 (376)

Clinical pharmacology considerations for first-in-human clinical trials for enzyme replacement therapy. [PDF]

J Inherit Metab Dis
Stern S, Wang J, Li RJ, Hon YY, Weis SL, Wang YC, Schuck R, Pacanowski M.   +7 more
europepmc   +1 more source

Presbycusis: Pathology, Signal Pathways, and Therapeutic Strategy

Advanced Science, EarlyView.
In ARHL, the stria vascularis, acting as a cochlear battery, gradually loses its ability to maintain the endocochlear potential, leading to impaired hair cell function and progressive hearing loss. Single‐cell sequencing reveals age‐related cellular changes in the cochlea, providing insights into the underlying mechanisms of aging and potential ...
Xiaoxu Zhao, Tian Shen, Shengda Cao, Ziyi Liu, Wendu Pang, Meixuan Li, Jingjing Liu, Wen Li, Yunhao Wu, Chengcheng Liu, Ming Xia, Xiaolong Fu, Cheng Cheng   +12 more
wiley   +1 more source

A Modified Delphi Study to Establish Essential Clinical Pharmacology Competencies. [PDF]

Ther Innov Regul Sci
Johnson-Williams B, Reynolds K, Gobburu J, Rundio A.   +3 more
europepmc   +1 more source

Advances in Electrical Materials for Bone and Cartilage Regeneration: Developments, Challenges, and Perspectives

Advanced Science, EarlyView.
This review explores the challenges of treating bone and cartilage defects, emphasizing the role of endogenous electric fields in bone and cartilage regeneration. It highlights recent advancements in electroactive biomaterials, including nanogenerators, piezoelectric materials, triboelectric scaffold, and zwitterionic hydrogels.
Yubin Yao, Xi Cui, Shenglong Ding, Ketao Wang, Mingzhu Zhang   +4 more
wiley   +1 more source

Clinical pharmacology of 2, 3-dichloro-4-methoxyphenyl 2-furyl ketone (E)-0- [2-(diethylamino) ethyl] oxime (ANP 4364) in healthy volunteers

, 1979
Mitsuyoshi Nakashima, Kunifumi Suzuki, Hisakuni Hashimoto, Katsunori Oguro, Kenji Nishijima   +4 more
openalex   +2 more sources

Comprehensive and robust stability-indicating reversed phase high performance liquid chromatography (RP-HPLC) method for Rivaroxaban: synergistic integration of infrared spectroscopy and clinical pharmacology insights. [PDF]

Front Chem
Mestareehi A.
europepmc   +1 more source

Inhibition of RACK1‐Mediated NLRP3 Oligomerization (Active Conformation) Ameliorates Acute Respiratory Distress Syndrome

Advanced Science, EarlyView.
Schematic diagram showing the potential mechanism of bigelovin on the activation of NLRP3 inflammasome Bigelovin may inhibit activated protein C kinase 1 (RACK1) by directly binding with cys168 of RACK1. Bigelovin thus prevents oligomerization of NLRP3 (NLRP3 active conformation) and subsequent assembly of NLRP3 inflammasome, blocking the activation of
Jian Cui, Meng Yang, Chengli Yu, Haidong Zhang, Yuan Gong, Yang Hu, Yue Wang, Qingxin Yuan, An Pan, Jiepin Li, Yaowen Hu, Zecheng Jin, Xuemei Peng, Anyuan Wu, Junwei Wang, Qian Wang, Yinan Zhang, Lihong Hu   +17 more
wiley   +1 more source

Clinical pharmacological studies on serum dopamine β-hydroxylase

, 1978
Miyako Baba, Kazuo Sawami, Tadao Itoh, S. Yoshida   +3 more
openalex   +1 more source

Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug-Drug Interactions. [PDF]

Pharmaceutics
Ferri N, Colombo E, Corsini A.
europepmc   +1 more source

Enhancer Profiling Reveals a Protective Role of RXRα Against Calcium Oxalate‐Induced Crystal Deposition and Kidney Injury

Advanced Science, EarlyView.
Comprehensive epigenomic and transcriptomic profiling revealed a dynamic enhancer landscape and gene expression program associated with nephrolithiasis, highlighting RXRα as a central transcription factor in this regulatory network. Tubular‐specific deletion of RXRα increased intrarenal CaOx crystal deposition, while its activation with Bexarotene ...
Yu Yang, Xudan Dou, Yongzhan Sun, Mengyao Wang, Jing Wang, Xinyi Cao, Haijie Xie, Linguo Xie, Weiping Tian, Jing Nie, Yupeng Chen, Chunyu Liu, Lirong Zhang   +12 more
wiley   +1 more source